Recent Updates
Recently added Catalysts
RADX Neutral Sentiment Score: 60/100

Appendix 2A - Application for quotation of securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Announcement Type New announcement Date of this announcement Thursday

Key Takeaway: Radiopharm Theranostics Limited announced its application for the quotation of securities on the ASX, specifically for 20,594,438 ordinary fully paid shares. This announcement is part of its compliance with ASX Listing Rules, and the securities are already classified under an existing class. As the application suggests an ongoing process, further details on the circumstances surrounding this issuance may be provided in future communications.

Market Sentiment Analysis

POSITIVE FACTORS

  • Application for quotation of newly issued securities shows confidence in market.
  • The total number of securities issued is substantial, indicating growth potential.

Full Press Release Details

Announcement Summary
RADIOPHARM THERANOSTICS LIMITED
Date of this announcement
Thursday December 19, 2024
The +securities to be quoted are:
Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.
Total number of +securities to be quoted
Number of +securities to
ASX +security code Security description be quoted Issue date
RAD ORDINARY FULLY PAID 20,594,438 13/12/2024
Refer to next page for full details of the announcement
RADIOPHARM THERANOSTICS LIMITED
We (the entity named above) apply for +quotation of the
following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.
1.2 Registered number type Registration number
ACN 647877889
1.3 ASX issuer code
RAD
1.4 The announcement is
1.5 Date of this announcement
2.1 The +securities to be quoted are:
Please refer to the response to Q2.3d for further information
about the type of securities to be quoted and the circumstances of the issue.
2.2 The +class of +securities to be quoted is:
Additional +securities in a class that is already quoted on
ASX ("existing class")
2.3c Have these +securities been offered under a +disclosure
2.3d Please provide any further information needed to
understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities
has not been previously announced to the market in an Appendix 3B
2.4 Any on-sale of the +securities to be quoted within
12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act
The publication of a cleansing notice under section 708A(5),
708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
Part 3B - number and type of +securities to be
quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B
Additional +securities to be quoted in an existing class
ASX +security code and description
RAD : ORDINARY FULLY PAID
Will the +securities to be quoted rank equally in all
respects from their issue date with the existing issued +securities in that class?
Number of +securities to be quoted
Are the +securities being issued for a cash consideration?
describe the consideration being provided for the +securities
Please provide an estimate (in AUD) of the value of
the consideration being provided per +security for the +securities to be quoted
Any other information the entity wishes to provide about
the +securities to be quoted
The purpose(s) for which the entity is issuing the securities
Please provide additional details
Following the quotation of the +securities the subject
of this application, the issued capital of the entity will comprise:
The figures in parts 4.1 and 4.2 below are automatically generated
and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX
4.1 Quoted +securities (total number of each +class
of +securities quoted on ASX following the +quotation of the +securities subject of this application)
Total number of +securities
ASX +security code and description on issue
RADO : OPTION EXPIRING 30-NOV-2026 79,352,040
RAD : ORDINARY FULLY PAID 2,193,555,194
RADOA : OPTION EXPIRING 24-AUG-2026 818,890,534
4.2 Unquoted +securities (total number of each +class of
+securities issued but not quoted on ASX)
Total number
ASX +security code and description of +securities on issue
RADAK : OPTION EXPIRING 01-JUN-2027 EX $0.60 2,500,000
RADAE : OPTION EXPIRING 25-NOV-2025 RESTRICTED 5,700,006
RADAN : OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES 72,262,387
RADAJ : OPTION EXPIRING 01-JUL-2027 EX $0.17 13,137,976
RADAF : OPTION EXPIRING 25-NOV-2026 RESTRICTED 8,666,678
RADAG : OPTION EXPIRING 25-NOV-2026 EX $0.60 5,066,672
RADAH : OPTION EXPIRING 22-DEC-2025 EX $0.60 400,000
RADAI : OPTION EXPIRING 27-MAY-2027 EX $0.60 740,000
RADAP : OPTION EXPIRING 24-APR-2028 EX $0.09 8,955,224
RADAAA : OPTION EXPIRING 24-FEB-2025 EX $0.05 149,925,040
5.1 Are the +securities being issued under an exception
in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?
5.1a Select the number of the applicable
exception in Listing Rule 7.2

Frequently Asked Questions

What securities will Radiopharm Theranostics issue?

Radiopharm Theranostics will issue 20,594,438 ordinary fully paid securities.

When will the securities be quoted?

The securities will be quoted on December 13, 2024.

How many total securities will be quoted after this issue?

A total of 2,193,555,194 ordinary fully paid securities will be quoted.

Will the new securities rank equally with existing ones?

Yes, the new securities will rank equally with existing issued securities.

Is a cash consideration required for the new securities?

Further details about the consideration for the new securities were not provided.

Last updated: Dec 19, 2024